Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Teva Pharmaceuticals soars after Warren Buffett's Berkshire Hathaway discloses a stake (TEVA) | Markets Insider
Teva Pharmaceuticals moving HQ to New Jersey – thereporteronline
FDA approves Teva's generic EpiPen after yearslong delay
Teva Says 2018 Profit Will Keep Falling as Generic Drug Slump Persists - Bloomberg
Teva | Partnership | Direct Relief
Teva Pharmaceutical Industries Limited 2018 Q4 - Results - Earnings Call Slides (NYSE:TEVA) | Seeking Alpha
Teva recalls US-made drugs following contamination fears - The Boston Globe
Teva Pharmaceutical begins first wave of layoffs in Kansas - Kansas City Business Journal
Reflecting on a Year of Remarkable Achievements and Resilience at Teva Pharmaceuticals
A Deep Dive into Teva Pharma Financials Shows Significant Weakness and Optimism | BioSpace
Teva selects North Jersey site for its new North American headquarters. - Philadelphia Business Journal
Teva Pharmaceuticals considering 345,000 sq. ft. in Parsippany | Parsippany Focus
Teva Pharmaceutical reports Q1 2018 | AlphaStreet
Here's Why Teva Pharma Stock Is Soaring Today
Drug Maker Teva to Pay Over $500 Million in New York Drug Case Settlement - The New York Times
Lured by $40 million tax break, Teva moving U.S. headquarters from Pa. to North Jersey - WHYY
Teva Reports Massive $11.6 Billion Loss, Predicts Weak 2018 - Business - Haaretz.com
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
Teva Pharmaceutical Industries (NASDAQ:TEVA) Share Price | RNS News, Quotes, & Charts | TEVA
Teva Is the 23rd Drug Maker to Impose Limits on 340B Contract Pharmacies - 340B Report
Teva Pharmaceuticals - Wikipedia
Teva restructuring hits American HQ, claiming 200-plus Pennsylvania jobs | Fierce Pharma
Teva down as it reports lower sales and profit for 2018
